North America Colorectal Cancer Screening Market Size, Share & Industry Trends Analysis Report By Type (Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), By End-user, By Country and Growth Fore

North America Colorectal Cancer Screening Market Size, Share & Industry Trends Analysis Report By Type (Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), By End-user, By Country and Growth Forecast, 2023 - 2030


The North America Colorectal Cancer Screening Market would witness market growth of 4.2% CAGR during the forecast period (2023-2030).

Due to technological advancements in biotech, favorable policies and the affordability of DNA sequencing will further assure market growth. The FDA recently approved a faecal DNA test and a blood test to detect colorectal cancer to address market requirements for minimally intrusive diagnosis. Improvements in industrial genetics have enabled DNA sequencing with elevated speeds and at affordable costs, increasing the adoption rate for in-vitro colorectal cancer screening tests, thus widening the market prospects. Research and development activities focusing on developing superior DNA sequencing techniques, like RNA polymerase (RNAP) sequencing, microfluidic Sanger sequencing, and hybridization, will substantially affect the growth of this market.

The trend towards personalized medicine has led to the development of screening methods that consider individual risk factors, tailoring screening recommendations based on factors such as family history and genetics. Personalized medicine in the context of colorectal cancer screening involves tailoring screening strategies and interventions based on an individual's unique risk factors, genetic profile, medical history, and other relevant characteristics. This approach aims to provide more targeted and effective screening recommendations, thereby improving the early detection and management of colorectal cancer.

For the treatment and diagnosis of colorectal cancer, the United States and Canada have a well-structured healthcare system. The region's market is anticipated to increase due to factors like the increasing colorectal cancer prevalence rate, rising research funding, and rising market innovations by significant players. Also, according to the same source, in the United States, approximately nine out of ten people with colorectal cancer who are diagnosed early and treated appropriately are still alive five years later. The regional market is expected to rise due to the high prevalence of colorectal cancer and the rising need for screening.

The US market dominated the North America Colorectal Cancer Screening Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $6.6 billion by 2030. The Canada market is poised to grow at a CAGR of 6.6% during (2023 - 2030). Additionally, The Mexico market is would register a CAGR of 5.7% during (2023 - 2030).

Based on Type, the market is segmented into Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), and Others. Based on End-user, the market is segmented into Government, Energy, Defense, Agriculture & Forestry, Media & Entertainment, Civil Engineering & Archaeology, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novigenix SA, Eiken Chemical Co., Ltd., Clinical Genomics Pathology, Inc., Exact Sciences Corporation, Epigenomics AG, BioMerieux S.A., Olympus Corporation, Sysmex Corporation, Fujifilm Holdings Corporation, and Siemens Healthineers AG (Siemens AG)

Scope of the Study

Market Segments covered in the Report:

By Type
  • Colonoscopy
  • Stool-based
  • Fecal Immunochemical Test (FIT)
  • Fecal Occult Blood Test (FOBT)
  • Stool-DNA Test
  • Others
By End-user
  • Hospitals & Clinics
  • Clinical Laboratories
  • Diagnostic Imaging Centres
  • Others
By Country
  • US
  • Canada
  • Mexico
  • Rest of North America
Companies Profiled
  • Novigenix SA
  • Eiken Chemical Co., Ltd.
  • Clinical Genomics Pathology, Inc.
  • Exact Sciences Corporation
  • Epigenomics AG
  • BioMerieux S.A.
  • Olympus Corporation
  • Sysmex Corporation
  • Fujifilm Holdings Corporation
  • Siemens Healthineers AG (Siemens AG)
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Colorectal Cancer Screening Market, by Type
1.4.2 North America Colorectal Cancer Screening Market, by End-user
1.4.3 North America Colorectal Cancer Screening Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Geographical Expansions
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Mergers & Acquisition: 2019, Jul – 2022, Dec) Leading Players
4.4 Porter’s Five Forces Analysis
Chapter 5. North America Colorectal Cancer Screening Market by Type
5.1 North America Colonoscopy Market by Country
5.2 North America Stool-based Market by Country
5.3 North America Colorectal Cancer Screening Market by Stool-based Type
5.3.1 North America Fecal Immunochemical Test (FIT) Market by Country
5.3.2 North America Fecal Occult Blood Test (FOBT) Market by Country
5.3.3 North America Stool-DNA Test Market by Country
5.4 North America Others Market by Country
Chapter 6. North America Colorectal Cancer Screening Market by End-user
6.1 North America Hospitals & Clinics Market by Country
6.2 North America Clinical Laboratories Market by Country
6.3 North America Diagnostic Imaging Centres Market by Country
6.4 North America Others Market by Country
Chapter 7. North America Colorectal Cancer Screening Market by Country
7.1 US Colorectal Cancer Screening Market
7.1.1 US Colorectal Cancer Screening Market by Type
7.1.1.1 US Colorectal Cancer Screening Market by Stool-based Type
7.1.2 US Colorectal Cancer Screening Market by End-user
7.2 Canada Colorectal Cancer Screening Market
7.2.1 Canada Colorectal Cancer Screening Market by Type
7.2.1.1 Canada Colorectal Cancer Screening Market by Stool-based Type
7.2.2 Canada Colorectal Cancer Screening Market by End-user
7.3 Mexico Colorectal Cancer Screening Market
7.3.1 Mexico Colorectal Cancer Screening Market by Type
7.3.1.1 Mexico Colorectal Cancer Screening Market by Stool-based Type
7.3.2 Mexico Colorectal Cancer Screening Market by End-user
7.4 Rest of North America Colorectal Cancer Screening Market
7.4.1 Rest of North America Colorectal Cancer Screening Market by Type
7.4.1.1 Rest of North America Colorectal Cancer Screening Market by Stool-based Type
7.4.2 Rest of North America Colorectal Cancer Screening Market by End-user
Chapter 8. Company Profiles
8.1 Novigenix SA
8.1.1 Company Overview
8.1.2 SWOT Analysis
8.2 Eiken Chemical Co., Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.3 Clinical Genomics Pathology, Inc.
8.3.1 Company Overview
8.3.2 Recent strategies and developments:
8.3.2.1 Partnerships, Collaborations, and Agreements:
8.3.3 SWOT Analysis
8.4 Exact Sciences Corporation
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.4.6 SWOT Analysis
8.5 Epigenomics AG
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 SWOT Analysis
8.6 BioMerieux S.A.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Acquisition and Mergers:
8.6.6 SWOT Analysis
8.7 Olympus Corporation
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.7.5.2 Product Launches and Product Expansions:
8.7.5.3 Acquisition and Mergers:
8.7.6 SWOT Analysis
8.8 Sysmex Corporation
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 Siemens Healthineers AG (Siemens AG)
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.9.4.1 Acquisition and Mergers:
8.9.5 SWOT Analysis
8.10. Fujifilm Holdings Corporation
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 Recent strategies and developments:
8.10.5.1 Partnerships, Collaborations, and Agreements:
8.10.5.2 Product Launches and Product Expansions:
8.10.5.3 Geographical Expansions:
8.10.6 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings